Nifty
Sensex
:
:
24870.10
81306.85
-213.65 (-0.85%)
-693.86 (-0.85%)

Pharmaceuticals & Drugs - Global

Rating :
52/99

BSE: 543064 | NSE: COHANCE

884.70
22-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  892
  •  893.95
  •  882.05
  •  898.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  105334
  •  93363158.6
  •  1360
  •  882.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,845.71
  • 132.22
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 33,835.17
  • N/A
  • 19.28

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 66.41%
  • 7.41%
  • 6.40%
  • FII
  • DII
  • Others
  • 7.23%
  • 11.18%
  • 1.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.75
  • -7.31

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 1.07
  • -6.95

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 2.24
  • -12.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 34.76
  • 43.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 10.60
  • 10.99

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 36.18
  • 43.09

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
11.8
10.52
17.79
24.09
P/E Ratio
74.97
84.10
49.73
36.72
Revenue
1036
1198
3303
4017
EBITDA
406
1081
1401
Net Income
300
268
688
933
ROA
14.2
24.1
24.8
P/B Ratio
10.95
8.23
6.99
ROE
15.86
15.13
17.83
FCFF
301
399
603
FCFF Yield
0.72
0.96
1.45
Net Debt
-759
-115
-275
BVPS
80.76
107.47
126.6

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
549.31
488.08
12.55%
402.02
252.93
58.95%
307.15
219.82
39.73%
257.72
231.05
11.54%
Expenses
437.30
362.98
20.47%
328.46
179.59
82.89%
189.45
153.74
23.23%
153.71
132.41
16.09%
EBITDA
112.01
125.10
-10.46%
73.56
73.34
0.30%
117.70
66.08
78.12%
104.01
98.64
5.44%
EBIDTM
20.39%
25.63%
18.30%
29.00%
38.32%
30.06%
40.36%
42.69%
Other Income
14.17
19.41
-27.00%
10.57
17.06
-38.04%
15.71
14.34
9.55%
14.12
19.84
-28.83%
Interest
10.18
10.20
-0.20%
5.75
2.30
150.00%
3.33
2.16
54.17%
1.67
1.14
46.49%
Depreciation
45.14
31.28
44.31%
26.78
17.25
55.25%
20.35
12.79
59.11%
16.96
11.95
41.92%
PBT
62.76
103.03
-39.09%
51.60
70.85
-27.17%
109.73
65.47
67.60%
99.50
105.39
-5.59%
Tax
16.36
27.66
-40.85%
12.87
17.48
-26.37%
26.44
18.72
41.24%
17.52
25.84
-32.20%
PAT
46.40
75.37
-38.44%
38.73
53.37
-27.43%
83.29
46.75
78.16%
81.98
79.55
3.05%
PATM
8.45%
15.44%
9.63%
21.10%
27.12%
21.27%
31.81%
34.43%
EPS
1.28
2.96
-56.76%
1.65
2.10
-21.43%
3.26
1.84
77.17%
3.23
3.12
3.53%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
1,516.20
1,051.35
1,340.33
1,320.22
1,009.72
833.79
377.83
Net Sales Growth
27.21%
-21.56%
1.52%
30.75%
21.10%
120.68%
 
Cost Of Goods Sold
389.83
311.39
402.97
394.05
297.56
225.32
101.46
Gross Profit
1,126.37
739.97
937.36
926.17
712.16
608.47
276.37
GP Margin
74.29%
70.38%
69.94%
70.15%
70.53%
72.98%
73.15%
Total Expenditure
1,108.92
645.54
766.17
738.50
566.72
449.03
206.28
Power & Fuel Cost
-
48.30
73.93
59.55
44.20
38.23
18.06
% Of Sales
-
4.59%
5.52%
4.51%
4.38%
4.59%
4.78%
Employee Cost
-
135.92
118.25
100.48
76.23
65.10
29.63
% Of Sales
-
12.93%
8.82%
7.61%
7.55%
7.81%
7.84%
Manufacturing Exp.
-
89.05
109.62
129.24
105.31
83.89
35.11
% Of Sales
-
8.47%
8.18%
9.79%
10.43%
10.06%
9.29%
General & Admin Exp.
-
35.90
33.87
28.99
27.73
25.97
12.62
% Of Sales
-
3.41%
2.53%
2.20%
2.75%
3.11%
3.34%
Selling & Distn. Exp.
-
10.35
17.64
19.80
10.53
9.43
6.72
% Of Sales
-
0.98%
1.32%
1.50%
1.04%
1.13%
1.78%
Miscellaneous Exp.
-
14.63
9.90
6.37
5.16
1.08
2.69
% Of Sales
-
1.39%
0.74%
0.48%
0.51%
0.13%
0.71%
EBITDA
407.28
405.81
574.16
581.72
443.00
384.76
171.55
EBITDA Margin
26.86%
38.60%
42.84%
44.06%
43.87%
46.15%
45.40%
Other Income
54.57
61.91
46.36
92.38
14.24
18.12
0.60
Interest
20.93
7.45
12.81
8.53
11.67
23.07
2.79
Depreciation
109.23
54.60
47.99
39.10
31.64
23.51
11.50
PBT
323.59
405.67
559.73
626.48
413.94
356.30
157.87
Tax
73.19
105.39
148.44
213.78
105.33
87.51
48.59
Tax Rate
22.62%
25.98%
26.52%
34.12%
25.45%
24.56%
30.78%
PAT
250.40
300.28
411.29
453.80
308.61
268.79
109.27
PAT before Minority Interest
255.98
300.28
411.29
453.80
308.61
268.79
109.27
Minority Interest
5.58
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
16.51%
28.56%
30.69%
34.37%
30.56%
32.24%
28.92%
PAT Growth
-1.82%
-26.99%
-9.37%
47.05%
14.81%
145.99%
 
EPS
6.54
7.85
10.75
11.86
8.07
7.03
2.86

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
2,050.66
1,735.18
1,527.18
1,180.81
844.76
590.29
Share Capital
25.46
25.46
25.46
25.46
12.73
0.00
Total Reserves
2,023.21
1,709.73
1,501.72
1,155.35
832.03
577.56
Non-Current Liabilities
96.53
71.79
92.11
73.91
127.68
35.12
Secured Loans
0.00
4.56
28.44
35.59
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
91.25
0.00
Long Term Provisions
10.50
8.30
8.89
6.65
8.31
5.95
Current Liabilities
206.06
303.09
347.52
321.51
319.85
190.67
Trade Payables
42.36
70.09
105.90
82.93
71.06
53.57
Other Current Liabilities
21.22
19.84
29.54
28.57
27.51
19.47
Short Term Borrowings
38.58
64.60
67.13
105.64
94.04
82.79
Short Term Provisions
103.90
148.56
144.94
104.36
127.24
34.83
Total Liabilities
2,353.25
2,110.06
1,966.81
1,576.23
1,292.29
816.08
Net Block
669.62
663.33
534.19
441.16
356.74
270.90
Gross Block
927.38
875.60
693.81
569.62
456.66
347.41
Accumulated Depreciation
257.76
212.27
159.62
128.46
99.91
76.51
Non Current Assets
990.90
954.70
701.66
909.68
781.17
393.28
Capital Work in Progress
179.08
165.09
29.99
96.32
101.71
111.07
Non Current Investment
130.58
117.10
117.10
361.19
307.46
0.07
Long Term Loans & Adv.
11.41
9.19
13.07
10.85
15.06
11.02
Other Non Current Assets
0.20
0.00
7.30
0.16
0.20
0.22
Current Assets
1,362.35
1,155.37
1,265.16
666.54
511.12
422.80
Current Investments
773.90
418.94
481.22
180.59
30.67
7.06
Inventories
231.20
312.81
283.42
201.08
174.87
157.10
Sundry Debtors
133.66
110.94
236.37
102.38
117.20
147.50
Cash & Bank
50.50
68.01
47.31
9.65
14.07
12.90
Other Current Assets
173.09
11.46
9.15
56.03
174.30
98.24
Short Term Loans & Adv.
161.19
233.21
207.69
116.80
134.56
37.32
Net Current Assets
1,156.29
852.28
917.64
345.04
191.27
232.13
Total Assets
2,353.25
2,110.07
1,966.82
1,576.22
1,292.29
816.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
358.48
457.20
330.00
382.55
406.92
50.40
PBT
405.67
559.73
667.59
467.67
404.51
157.87
Adjustment
15.35
37.46
40.63
36.48
34.60
13.93
Changes in Working Capital
47.41
5.77
-193.97
-12.17
54.21
-88.33
Cash after chg. in Working capital
468.43
602.96
514.26
491.98
493.33
83.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-109.95
-145.76
-184.26
-109.44
-86.41
-33.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-362.25
-195.01
-136.14
-311.40
-413.45
-65.48
Net Fixed Assets
-65.47
-154.01
-57.86
-107.57
-99.89
Net Investments
-374.60
-110.17
-173.65
-149.92
-269.19
Others
77.82
69.17
95.37
-53.91
-44.37
Cash from Financing Activity
-13.80
-241.95
-156.48
-75.66
7.32
25.98
Net Cash Inflow / Outflow
-17.57
20.24
37.38
-4.51
0.79
10.90
Opening Cash & Equivalents
64.80
44.56
7.18
11.70
10.90
0.00
Closing Cash & Equivalent
47.23
64.80
44.56
7.18
11.70
10.90

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
80.48
68.16
59.99
46.39
33.18
0.00
ROA
13.46%
20.18%
25.62%
21.52%
25.50%
13.39%
ROE
15.87%
25.21%
33.52%
30.47%
37.80%
18.92%
ROCE
21.22%
33.41%
45.92%
36.19%
44.55%
23.87%
Fixed Asset Turnover
1.17
1.71
2.09
1.97
2.07
1.09
Receivable days
42.46
47.25
46.80
39.69
57.94
142.49
Inventory Days
94.43
81.11
66.93
67.95
72.66
151.76
Payable days
65.90
79.70
87.45
94.44
49.88
86.75
Cash Conversion Cycle
70.98
48.66
26.27
13.19
80.72
207.50
Total Debt/Equity
0.02
0.04
0.06
0.12
0.22
0.14
Interest Cover
55.44
44.69
79.29
36.48
16.45
57.60

News Update:


  • USFDA completes GMP inspection at Cohance Lifesciences’ Hyderabad facility
    14th Aug 2025, 10:30 AM

    Following the inspection, the Company has received a Form 483 from the USFDA with 06 observations

    Read More
  • Cohance Lifesciences - Quarterly Results
    13th Aug 2025, 17:14 PM

    Read More
  • Cohance Lifesciences to invest $10 million to expand cGMP bioconjugation capabilities at U.S based subsidiary
    12th Aug 2025, 17:45 PM

    NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

    Read More
  • Cohance Lifesciences enters into agreements with Chromo Laboratories India
    20th Jun 2025, 15:00 PM

    The said transaction is expected to be completed in Q2 FY26, subject to satisfaction of customary closing conditions under the said agreements

    Read More
  • Cohance Lifesciences receives EIR from USFDA for API Unit-IV in Telangana
    26th May 2025, 09:37 AM

    The inspection was classified as VAI and indicates the formal closure of the inspection process by the USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.